Table 7.
Study name | Study groups with number of new infections | Risk (R) | Risk ratio (RR) (95% CI) | P value | Interpretation for the RR values |
---|---|---|---|---|---|
Sawa et al., 2013 [34] | DP (n/N): 0/137 AL (n/N): 8/147 |
0.00 0.054 |
0.063 (0.004–1.083) |
0.057 | There has been 37% reduction in new infections associated with DP treatment but reduction is not statistically significant. |
| |||||
Yavo et al., 2011 [33] | DP (n/N): 1/191 AL (n/N): 3/183 |
0.005 0.016 |
0.319 (0.034–3.042) |
0.321 | There was a 68% reduction in new infections in favour of DP treatment but result not statistically significant. |
| |||||
Bassat et al., 2009 [32] | DP (n/N): 27/1038 AL (n/N): 64/510 |
0.026 0.125 |
0.207 (0.134–0.321) |
<0.001 | This result shows 79% reduction in incidence of new falciparum infections in favour of DP treatment and the reduction is statistically significant. The lowest plausible reduction is 67.9% while the highest is 86.6% as defined by the 95% CI of the RR. |
| |||||
Mens et al., 2008 [31] | DP (n/N): 0/67 AL (n/N): 1/67 |
0.000 0.015 |
0.333 (0.014–8.039) |
0.499 | DP treatment was associated with a 66.7% reduction in risk for a patient to acquire new infections compared to AL. The reduction is not statistically significant. |